Q-omics provides the consensus-scored MIR608 profile across patient tissues and cancer cell-line models. MIR608 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MIR608 is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, MIR608 RNA expression shows 11,166 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight MESO, STAD, and ESCA as cancer lineages where MIR608 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR608 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR608 survival associations across molecular data types. MIR608 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR608 RNA expression–survival associations across cancer types. High MIR608 expression shows unfavorable associations in MESO, LUSC, UVM, TGCT and UCEC, but favorable associations in HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MIR608 RNA expression.
This table summarizes MIR608 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR608. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR608 shows higher tumor expression in STAD. The STAD box plot shows higher MIR608 RNA expression in tumor versus normal tissue (log2 FC = +0.482, t-test p = .016).
This table shows molecular features associated with MIR608 in patient tissues and cancer cell lines. In patient samples, MIR608 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
